97 related articles for article (PubMed ID: 18948412)
1. Use of an exposure-response model to aid early drug development of an oral sphingosine 1-phosphate receptor modulator.
Rohatagi S; Zahir H; Moberly JB; Truitt KE; Inaba S; Shimozato T; Carrothers TJ
J Clin Pharmacol; 2009 Jan; 49(1):50-62. PubMed ID: 18948412
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients.
Moberly JB; Ford DM; Zahir H; Chen S; Mochizuki T; Truitt KE; Vollmer TL
J Neuroimmunol; 2012 May; 246(1-2):100-7. PubMed ID: 22465063
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological modulation of peripheral T and B lymphocytes by a selective sphingosine 1-phosphate receptor-1 modulator.
Moberly JB; Rohatagi S; Zahir H; Hsu C; Noveck RJ; Truitt KE
J Clin Pharmacol; 2012 Jul; 52(7):996-1006. PubMed ID: 21566200
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of species difference in peripheral lymphocyte reduction effect of CS-0777, a sphingosine 1-phosphate receptor modulator, based on a pharmacokinetic/pharmacodynamic model analysis.
Inaba SI; Goto M; Tanaka-Takanaka K; Tanaka H; Tomisato W; Yuita H; Doi-Komuro H; Inoue R; Oshima K; Kagari T; Shimozato T; Izumi T
Biopharm Drug Dispos; 2016 Dec; 37(9):561-573. PubMed ID: 27764535
[TBL] [Abstract][Full Text] [Related]
5. The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.
Ohno T; Hasegawa C; Nakade S; Kitagawa J; Honda N; Ogawa M
Biopharm Drug Dispos; 2010 Oct; 31(7):396-406. PubMed ID: 20623701
[TBL] [Abstract][Full Text] [Related]
6. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects.
Kovarik JM; Schmouder R; Barilla D; Riviere GJ; Wang Y; Hunt T
J Clin Pharmacol; 2004 May; 44(5):532-7. PubMed ID: 15102874
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of fingolimod phosphate in healthy participants.
Wu K; Mercier F; David OJ; Schmouder RL; Looby M
J Clin Pharmacol; 2012 Jul; 52(7):1054-68. PubMed ID: 22110161
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and disposition of CS-0777, a sphingosine 1-phosphate receptor modulator, in rats and monkeys.
Inaba S; Ikeda T; Goto M; Tanaka H; Takahashi M; Iwabuchi H; Izumi T
Xenobiotica; 2015; 45(12):1063-80. PubMed ID: 26084376
[TBL] [Abstract][Full Text] [Related]
9. Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects.
Kovarik JM; Hartmann S; Bartlett M; Riviere GJ; Neddermann D; Wang Y; Port A; Schmouder RL
Biopharm Drug Dispos; 2007 Mar; 28(2):97-104. PubMed ID: 17230596
[TBL] [Abstract][Full Text] [Related]
10. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
11. Modeling the Effect of the Selective S1P
Lott D; Krause A; Seemayer CA; Strasser DS; Dingemanse J; Lehr T
Pharm Res; 2017 Mar; 34(3):599-609. PubMed ID: 28028771
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide.
Stark JG; Werner S; Homrighausen S; Tang Y; Krieg M; Derendorf H; Moellmann H; Hochhaus G
J Pharmacokinet Pharmacodyn; 2006 Aug; 33(4):441-59. PubMed ID: 16633890
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic/pharmacodynamic modelling of 2-acetyl-4(5)-tetrahydroxybutyl imidazole-induced peripheral lymphocyte sequestration through increasing lymphoid sphingosine 1-phosphate.
Yu XQ; Kramer J; Moran L; O'Neill E; Nouraldeen A; Oravecz T; Wilson AG
Xenobiotica; 2010 May; 40(5):350-6. PubMed ID: 20175664
[TBL] [Abstract][Full Text] [Related]
14. Purification and identification of activating enzymes of CS-0777, a selective sphingosine 1-phosphate receptor 1 modulator, in erythrocytes.
Yonesu K; Kubota K; Tamura M; Inaba S; Honda T; Yahara C; Watanabe N; Matsuoka T; Nara F
J Biol Chem; 2011 Jul; 286(28):24765-75. PubMed ID: 21613209
[TBL] [Abstract][Full Text] [Related]
15. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation.
Piali L; Froidevaux S; Hess P; Nayler O; Bolli MH; Schlosser E; Kohl C; Steiner B; Clozel M
J Pharmacol Exp Ther; 2011 May; 337(2):547-56. PubMed ID: 21345969
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
17. Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow.
Maeda Y; Seki N; Sato N; Sugahara K; Chiba K
Int Immunol; 2010 Jun; 22(6):515-25. PubMed ID: 20497959
[TBL] [Abstract][Full Text] [Related]
18. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney.
Awad AS; Ye H; Huang L; Li L; Foss FW; Macdonald TL; Lynch KR; Okusa MD
Am J Physiol Renal Physiol; 2006 Jun; 290(6):F1516-24. PubMed ID: 16403835
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants.
Ettenger R; Schmouder R; Kovarik JM; Bastien MC; Hoyer PF
Pediatr Transplant; 2011 Jun; 15(4):406-13. PubMed ID: 21585629
[TBL] [Abstract][Full Text] [Related]
20. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
Singer B; Ross AP; Tobias K
Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
